Form 8-K - Current report:
SEC Accession No. 0001213900-24-016715
Filing Date
2024-02-26
Accepted
2024-02-26 08:00:31
Documents
17
Period of Report
2024-02-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0200618-8k_emmaus.htm   iXBRL 8-K 30695
2 FORM OF CONVERTIBLE PROMISSORY NOTE DUE FEBRUARY 24, 2025 ea0200618ex4-1_emmaus.htm EX-4.1 167136
3 EXCHANGE AGREEMENT DATED AS OF FEBRUARY 21, 2024 ea0200618ex10-1_emmaus.htm EX-10.1 31240
4 FORM OF JOINDER AGREEMENT AND AMENDMENT TO TRANSFER RESTRICTION AND VOTING AGREE ea0200618ex10-2_emmaus.htm EX-10.2 4944
  Complete submission text file 0001213900-24-016715.txt   450658

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE emma-20240221.xsd EX-101.SCH 3030
6 XBRL LABEL FILE emma-20240221_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE emma-20240221_pre.xml EX-101.PRE 22369
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0200618-8k_emmaus_htm.xml XML 3299
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

EIN.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 24673595
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)